Insmed TPIP Phase 2b in PAH meets primary endpoint with 35% PVR reduction (p<0.001)

INSMED Inc

Placebo-adjusted PVR reduction 35% (p<0.001); 6MWD improvement 35.5 m (p=0.003); NT-proBNP reduction 60% (p<0.001).
Once-daily TPIP well tolerated; 75% of patients titrated to max dose 640 µg; 90% completed study.
Insmed to engage FDA for Phase 3; PH-ILD Phase 3 by end 2025; PAH Phase 3 early 2026.
Common TEAEs: cough 40.6%, headache 31.9%, fatigue 10.1%; no deaths in study.
95% of completers enrolled in open-label extension (1,280 µg max dose allowed).

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.